Helixmith

Seoul, KR
Hybrid — also manufactures internal programs
Plasmid AAV
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-29
59.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (3) ○ EMA GMP ○ MHRA GMP

Quick Facts: Helixmith

Signal Score
59.0/100 (as of 2026-04-29)
Quality Compliance
Assessment pending
Headquarters
Seoul, KR
Modalities
Plasmid, AAV
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Helixmith

Hybrid developer + CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesPlasmid, AAV
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
1 manufacturing site: Seoul, KR
Modalities: Plasmid, AAV
Capacity assessment: 58.0/100
Sites: Seoul, KR
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
Recent Press3 articles
1 manufacturing site: Seoul, KR
Modalities: Plasmid, AAV
Capacity assessment: 58.0/100

Recent News 3 articles

general 2026-04-23
[Medical & Bio Briefs] Helixmith Submits Clinical Trial Protocol for Gene Therapy Engensis to US FDA, and More - 동아사이언스
[Medical & Bio Briefs] Helixmith Submits Clinical Trial Protocol for Gene Therapy Engensis to US FDA, and More  동아사이언스
Source →
general 2026-03-20
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals  Barchart
Source →
general 2026-03-20
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals  Barchart.com
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Plasmid CDMOs → AAV CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
Pharmaron Biologics
San Diego, CA · Shaoxing, CN
Signal Score: 85.6
AAV, Lentiviral, Plasmid
Yposkesi (SK Pharmteco)
Corbeil-Essonnes, France
Signal Score: 80.3
AAV, Lentiviral, Plasmid
Ascend Advanced Therapies
Philadelphia, PA
Signal Score: 78.1
AAV, Lentiviral, Plasmid